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Abstract 
Background and Purpose- Acute ischemic stroke (AIS) is intrinsically associated with age 
and its incidence is expected to increase along with the growing life expectancy. In AIS 
patients, impaired blood brain barrier (BBB) integrity is linked with intracerebral hemorrhage 
and worsened outcome. However, the mechanisms underlying this link are poorly understood 
thus specific therapeutic strategies to address it are lacking. Sirtuin 5 (SIRT5) is a member of 
the NAD (+)-dependent protein deacetylase family previously shown to be protective in 
cardiac ischemia/ reperfusion (I/R) injury. Yet, little is known about its putative role in I/R-
induced brain injury. The present study investigates the role of SIRT5 in a mouse model of 
I/R brain injury induced by transient middle cerebral artery occlusion (tMCAO) and in primary 
human brain microvascular endothelial cells (HBMVECs) exposed to hypoxia/reoxygenation 
(H/R). 
Methods and results- SIRT5 knockout (SIRT5-/-) and wild type (WT) mice were subjected to 
45 min of ischemia followed by 48 h of reperfusion. Deletion of SIRT5 decreased infarct size, 
improved neurological function and blunted systemic inflammation following stroke. Similarly, 
SIRT5 knockdown by siRNA decreased infarct size as compared to scrambled treated mice. 
Immunohistochemical analysis revealed decreased BBB leakage and occludin- a tight 
junction protein (TJP) - degradation in SIRT5-/- mice exposed to tMCAO as opposed to WT. In 
primary HBMVECs exposed to H/R, knockdown of SIRT5 decreased endothelial permeability 
and upregulated occludin and claudin-5 protein levels; this effect was prevented by 
pretreatment of HBMVECs with the PI3K inhibitor wortmannin. 
Conclusion- SIRT5 mediates I/R-mediated brain damage by increasing BBB permeability 
through degradation of the TJP occludin. This effect was also reproduced in HBMVECs 
exposed to H/R and was mediated by the PI3K/ Akt pathway thus, underlying the 
translational relevance of our findings. Our data shed new light on the mechanisms of I/R-
dependent brain damage and indicate SIRT5 as an interesting novel therapeutic target. 
Key words: SIRT5, blood brain barrier, tight junction proteins, PI3K/ Akt pathway 
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Introduction 1 
Stroke is the second-leading cause of death and a major cause of disability worldwide and its 2 
incidence is set to increase due to the currently growing life expectancy.1-3 In absolute 3 
numbers, 15 million people suffer stroke annually and, from these, more than 10 million die 4 
or are permanently disabled. Four out of five strokes are categorized as acute ischemic 5 
stroke (AIS), for which the only currently available treatments are thrombolytic agent and/or 6 
use of a mechanical clot retrieval device.4 However, unlike the success of reperfusion 7 
therapy in myocardial infarction, its usage in AIS patients is limited to less than 10% of all 8 
cases with no alternative treatment.5   9 
Accumulating evidence indicates the blood brain barrier (BBB) as a promising therapeutic 10 
target for AIS. The BBB is formed by a monolayer of microvascular endothelial cells joined 11 
together by tight junction proteins (TJPs), restricting the passage of substances into the 12 
central nervous system (CNS). During ischemia and subsequent reperfusion, the integrity of 13 
the BBB is disrupted resulting in the leakage of blood-borne proteins in the parenchyma. In 14 
clinical studies, BBB leakage is strongly associated with hemorrhagic transformation and 15 
worsened outcome in AIS patients.6, 7 As for the mechanisms, the vast majority of in vivo and 16 
in vitro studies coincide in that TJPs disruption and matrix metalloproteinase (MMP)-17 
dependent extracellular matrix degradation are the two crucial events accounting for BBB 18 
breakdown after stroke.8-11 In this regard, oxidative stress and inflammatory response are 19 
thought to be fundamental mediators.12 Yet, the molecular pathways involved in BBB 20 
disruption remain to be elucidated. 21 
Mammalian sirtuins (SIRTs) are a family of seven proteins associated with distinct biological 22 
functions such as control of aging, oxidative stress, inflammation, apoptosis and metabolic 23 
pathways. SIRTs mediate their effects by means of post-translational protein modifications. In 24 
particular, sirtuin 5 (SIRT5) is a NAD+-dependent protein desuccinylase and demalonylase, 25 
as well as a weak deacetylase. Multiple (patho-) physiological functions of SIRT5 are 26 
currently emerging. Of interest, SIRT5 knockout mice exhibit a 75 % increment in infarct size 27 
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following myocardial ischemia/reperfusion (I/R) injury.13 However, whether SIRT5 also plays 1 
any role in I/R brain injury remains unknown. 2 
In the present study, we investigated the effects of deletion and knockdown of SIRT5 on I/R-3 
induced brain damage with a specific focus on BBB integrity and TJPs expression using both 4 
in vivo transient middle cerebral artery occlusion (tMCAO) and in vitro hypoxia-reoxygenation 5 
(H/R) stroke models. 6 
Methods 7 
Animals 8 
Experiments were performed on 10–14-week-old male SIRT5 knockout (SIRT5-/-) mice and 9 
wild-type (WT) controls (C57BL/6J). SIRT5-/- mice were generated as described previously.14 10 
Briefly, SIRT5floxed mice were obtained by standard gene targeting procedures,15 using 129SV 11 
embryonic stem (ES) cells. Then, these animals were crossed with CMV-Cre transgenic 12 
mice16 to generate germline SIRT5-/- mice, which have been subsequently backcrossed for 5 13 
generations with C57BL/6J mice.  14 
In vivo SIRT5 silencing was performed as previously described.17 Briefly, pre-designed small 15 
interfering RNA (siRNA) targeting SIRT5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) 16 
were injected intravenously in a randomized way. As a negative control, scrambled siRNA 17 
(Microsynth, Balgach, Switzerland) was used (sense: 5’-UACACACUCUCGUCUCU[dT][dT]-18 
3’; antisense: 5’-AGAGACGAGAGUGUGUA[dT][dT]-3’). 24 h before the surgical procedure, 19 
1.6 nmol of siRNA were incubated with a mixture of 150 mM NaCl solution–jetPEI® (Polyplus 20 
TransfectionTM, New York, NY, USA) delivery reagent for 15 min and injected into the tail 21 
vein. 22 
Animals were maintained at 24ºC under a 12 h light/dark cycle and were fed on a normal 23 
chow diet with ad libitum access to food and water. Study design and experimental protocols 24 
were approved by the institutional animal care committee (License no. TVA 293_2014; 25 
Kommission für Tierversuche des Kantons Zürich, Switzerland). 26 
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Middle Cerebral Artery Occlusion 1 
tMCAO was performed to induce I/R brain injury, as described previously.18, 19 Mice were 2 
anaesthetized using isoflurane 3 % and 1.5 % for induction and maintenance respectively, 3 
while body temperature was kept at 37°C. For analgesia, 0.5% bupivacaine was infiltrated at 4 
the incision side. The common, internal and external carotid arteries were dissected and a 6-5 
0 silicone-coated filament (Doccol Corporation, Sharon, MA, USA) was inserted into the 6 
common carotid artery and advanced to the origin of the left MCA to prompt tMCAO for 45 7 
min. After ischemia, middle cerebral artery (MCA) reperfusion was allowed for 24 h or 48 h. 8 
During anesthesia, regional cerebral blood flow (rCBF) in the area of the cortex supplied by 9 
the MCA was measured using laser Doppler flowmetry (PeriFluxSystem 5000 with probe 10 
model no. 418-1, Perimed AB, Jărfălla, Sweden). The microtip probe was positioned and 11 
glued ∼2 mm posterior and 6 mm lateral to the bregma. 12 
Stroke Volume 13 
Murine brains were cut into 4 equally spaced (2 mm) coronal sections and immersed in a 2% 14 
solution of 2,3,5-triphenyltetrazolium chloride (TTC) (Sigma-Aldrich, Chemie GmbH, Buchs, 15 
Switzerland) at 37°C for 20 min. Areas of infarction, ipsilateral and contralateral hemispheres 16 
were quantified using ImageJ software (Image J, NIH, MD, USA). To correct infarct size 17 
measurement for cerebral swelling and subsequent overestimation, we applied the following 18 
formula as already described:20 corrected infarct volume = contralateral hemisphere volume - 19 
(ipsilateral hemisphere volume - infarct volume). The infarct size was expressed as a 20 
percentage of the total contralateral hemisphere volume. 21 
Neurological Deficiency Assessment 22 
Neurological status was assessed by a four-point scale neurological score test according to 23 
Bederson et al.21: grade 0, normal neurological function; grade 1, forelimb flexion; grade 2, 24 
circling; grade 3, leaning to the contralateral side at rest; grade 4, no spontaneous motor 25 
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activity. An experimentator blinded to the group allocation evaluated the neurological deficit at 1 
2 h, 24 h and 48 h after tMCAO. 2 
Blood Sampling and Cell Count 3 
Blood samples were taken 48 h after tMCAO for measuring leukocytes, red blood cells and 4 
platelet counts using an impedance hematology analyzer (ScilVet ABCplus; Horiba, Kyoto, 5 
Japan). Data were expressed as neutrophils and lymphocytes percentages (relative to the 6 
total white blood cells) and neutrophil to lymphocytes ratio. 7 
Histology 8 
Histological procedures were performed as previously described.22 Briefly, following induction 9 
of deep anesthesia, mice were transcardially perfused with phosphate buffered saline (PBS) 10 
and 4.0% paraformaldehyde (PFA) (Sigma-Aldrich, Chemie GmbH, Buchs, Switzerland) in 11 
PBS at room temperature, followed by incubation in 30% sucrose in PBS for 36 h. 12 
Cryoprotected brains were cut into 100-µm thick free-floating sections pre-treated with 13 
proteinase K for antigen retrieval and immune-blocked. After these, they were incubated with 14 
primary antibodies at the following dilution occludin (1:200; Santa Cruz Biotechnology, Santa 15 
Cruz, CA, USA), the endothelial marker CD31 (1:50; BD Pharmingen, Allschwil, Switzerland ) 16 
and claudin-5 (1:200; Abcam, Cambridge, United Kingdom) at 4ºC overnight, respectively. 17 
After washing, brain sections were incubated with the appropriate secondary antibodies 18 
(Jackson Immunoresearch, West Grove, PA, USA) for 24 h at room temperature. Images 19 
were acquired using a confocal microscope (Leica SP8; Leica, Wetzlar, Germany). Stained 20 
area of claudin-5 and occludin was measured using ImageJ Software (Image J, NIH, MD, 21 
USA) and normalized to the total endothelial cell surface assessed by CD31 staining. 22 
BBB permeability was measured assessing endogenous immunoglobulin G (IgG) 23 
extravasation, sections were blocked for 60 min followed by incubation with Alexa647-24 
conjugated donkey anti-mouse IgG for 24 h (1:600; Jackson Immunoresearch, West Grove, 25 
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USA). IgG leakage was corrected for edema, as previously described in stroke volume 1 
assessment, and expressed as a percentage of the total contralateral hemisphere volume. 2 
Cell Culture Experiments 3 
Primary human brain microvascular endothelial cells (HBMVECs) (Cell Systems) between 4 
passage 6 and 8 were used for in vitro experiments. Endothelial cells were cultured in EBM-2 5 
medium (Lonza, Bettlach, Switzerland), supplemented with EGM-2 bullet kit (Lonza) and 6 
10% fetal bovine serum. Cells were grown to 80 % confluence before being transfected with 7 
SIRT5 siRNA (Santa Cruz Biotechnology, Santa Cruz, CA, USA) or scrambled siRNA 8 
(Microsynth, Balgach, Switzerland) for 24 h using Lipofectamine 3000 transfection kit 9 
according to manufacturer’s recommendation (Invitrogen, Carlsbad, CA, USA). Next, cells 10 
were exposed to hypoxia (0.2% oxygen) for 4 h followed by 4 h of reoxygenation (21% 11 
oxygen) or kept at normoxic condition (21% oxygen) for 8 h. Wortmannin (Enzo Life 12 
Sciences, Lausen, Switzerland) a PI3K inhibitor, in a final concentration of 10-7 M or dimethyl 13 
sulfoxide (DMSO) (Sigma-Aldrich, Chemie GmbH, Buchs, Switzerland) vehicle treatment was 14 
added to the HBMVECs cells 5 min before to hypoxia. Hypoxia was induced using a gas-15 
controlled glove hypoxia workstation (Invivo2 400, Baker Ruskinn, Sanford, ME, USA). 16 
Measurement of Barrier Function by Transendothelial Electrical Resistance 17 
Measurements of transendothelial electrical resistance (TEER) on HBMVEC monolayers 18 
were performed using the electric cell-substrate impedance system (ECIS) Z Theta system 19 
(Applied Biophysics, Troy, NY, USA) as previously described.23 The ECIS system provides 20 
real-time monitoring of changes in TEER. In brief, HBMVECs at 9x105/well were plated on 21 
fibronectin coated 8W10E+ electrode arrays (Applied Biophysics). Then, cells were allowed 22 
to form monolayers until stable TEER values were reached. After 5 h, the monolayers were 23 
treated with SIRT5 or scrambled siRNA as previously specified. Then, they were exposed to 24 
hypoxic conditions for 4 h followed by reoxygenation for 48 h. Wortmannin (10-7 M) or vehicle 25 
treatment (DMSO) was applied 5 min before to hypoxia. Measurements were conducted at 26 
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multiple frequencies ranging from 62.6 Hz to 64 kHz. Data were expressed as TEER percent 1 
change from baseline values (before hypoxia). 2 
Protein expression studies 3 
Protein expression was determined by Western blot analysis. Endothelial cells and aortae 4 
were homogenized in lysis buffer (Tris 50 mM, NaCl 150 mM, EDTA 1 mM, NaF 1 mM, DTT 1 5 
mM, aprotinin 10 mg/mL, leupeptin 10 mg/mL, Na3VO4  0.1 mM, phenylmethylsulfonyl 6 
fluoride (PMSF) 1 mM, and NP-40 0.5%). Protein concentration was determined according to 7 
the manufacturer’s recommendations (Bio-Rad Laboratores AG, Fribourg, Switzerland); 20 – 8 
30 µg of total protein lysates were separated on an 8 or 10% SDS–PAGE before being 9 
transferred  to a polyvinylidene fluoride membrane by wet transfer (Bio-Rad). Membranes 10 
were incubated with primary antibodies against SIRT5 (1:1000, Cell Signaling, Beverly, MA, 11 
USA), occludin (1:500, Santa Cruz Biotechnology, Santa Cruz, CA, USA), claudin-5 (1:1000, 12 
Invitrogen, Carlsbad, CA, USA), phospho-Akt (1:1000, Cell Signaling, Beverly, MA, USA), Akt 13 
(1:1000, Cell Signaling, Beverly, MA, USA) and glyceraldehyde 3-phosphate dehydrogenase 14 
(GAPDH) (1:40000, Merck Millipore, Billerica, MA,USA) at 4°C overnight on a shaker. 15 
Secondary antibodies (Southern Biotechnology, Birmingham, AL, USA) were applied for 1 h 16 
at room temperature. Densitometric analyses were performed (Amersham Imager 600, GE 17 
Healthcare Europe GmbH, Glattbrugg, Switzerland) and protein expression was normalized 18 
to GAPDH.   19 
Coimmunoprecipitation 20 
HBMVECs were lysed in ice-cold lysis buffer containing Tris 50 mM, NaCl 150 mM, EDTA 1 21 
mM, NaF 1 mM, DTT 1 mM, aprotinin 10 mg/mL, leupeptin 10 mg/mL, Na3VO4  0.1 mM, 22 
PMSF 1 mM, and NP-40 0.5%. Lysates were centrifuged at 10,000 g to remove insoluble 23 
material. For immunoprecipitation, precleared lysates were incubated with Akt antibody 24 
overnight at 4°C. Lysates were precleared by incubation with 50 μL of protein A/G-agarose 25 
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for 4 h at 4°C with rocking. Agarose beads were pelleted by centrifugation at 1000 g. 1 
Immunoprecipitated proteins were eluted from the beads by boiling for 5 min in SDS sample 2 
buffer and immunoblotted with primary antibodies against Akt (1:1000), claudin-5 (1:1000) 3 
and occludin (1:1000). Bound antibody was visualized using an enhanced 4 
chemiluminescence system (Merck Millipore, Billerica, MA, USA) after incubation of the blot 5 
with peroxidase-conjugated secondary antibody for 1 h. 6 
Statistical analysis 7 
Data were expressed as mean ± standard error of the mean (SEM). All statistical analyses 8 
were performed using GraphPad Prism 6 software (GraphPad Software, Inc, La Jolla, CA, 9 
USA). Results were confirmed to follow a normal distribution with the Kolmogorov-Smirnov 10 
test of normality. Data that passed the normality assumption were analyzed with two-tailed 11 
unpaired Student’s t-test and data that failed the normality assumption were analyzed with 12 
the nonparametric Mann–Whitney U test. For repeated measurements, two-way ANOVA with 13 
Sidak post hoc test was applied. A probability value (P) below 0.05 was considered 14 
statistically significant. 15 
Results 16 
Deletion as well as knockdown of SIRT5 reduces infarct size after 17 
ischemia/reperfusion brain injury 18 
To investigate the role of SIRT5 in stroke, SIRT5-/- and WT mice underwent MCAO for 45 min 19 
followed by 48 h of reperfusion. Measurement of rCBF by laser Doppler flowmetry in the 20 
region perfused by the MCA was similar between genotypes (P = NS for all time points; n = 21 
4-6; Figure S1 in Supplementary material). Deletion of SIRT5 reduced infarct size 22 
assessed by TTC staining at 48 h after tMCAO (WT: 40.93 ± 3.32% vs. SIRT5-/- : 19.60 ± 23 
3.67%; P = 0.0005; n = 9; Figure 1A-B). Reduced infarct size in SIRT5-/- mice was paralleled 24 
by reduced neurological deficit at 48 h compared to WT mice (WT: 1.07 ± 0.86 vs. SIRT5-/- : 25 
0.41 ± 0.66; P = 0.03; n = 13-12; Figure 1C). 26 
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To confirm these results using a different approach, in vivo knockdown of SIRT5 was 1 
performed by intravenous (i.v.) administration of SIRT5 siRNA mixed with a cationic 2 
transfection reagent.  First, SIRT5 silencing efficiency was assessed in vivo by measuring 3 
SIRT5 protein levels in aortic arteries. SIRT5 siRNA treated mice (siSIRT5) exhibited a 4 
reduced SIRT5 protein expression compared to scrambled siRNA treated mice (siSCR) at 48 5 
h after siRNA injection (siSCR: 1.00 ± 0.08 vs. siSIRT5: 0.61 ± 0.16; P = 0.046; n = 8-6; 6 
Figure S2A in the Supplementary material). In line with the SIRT5-/- mice data, siSIRT5 7 
mice presented reduced stroke size compared to siSCR mice at 24 h after tMCAO (siSCR: 8 
33.07 ± 1.83% vs. siSIRT5: 21.83 ± 3.05%; P = 0.004; n = 10-7; Figure 1D-E). There was 9 
not difference between groups in terms of post-stroke neurological score (data not shown). 10 
Deletion of SIRT5 reduces BBB disruption and tight junction protein (TJP) degradation 11 
I/R-induced BBB breakdown is characterized by extravasation of large circulating molecules, 12 
such as IgG into the affected parenchyma.24 As expected, IgG leakage was observed in the 13 
ipsilateral hemisphere of both WT and SIRT5-/- mice after stroke, while no IgG staining was 14 
found in the contralateral hemisphere (Figure 2A). IgG extravasation was significantly 15 
reduced in the SIRT5-/- mice compared to WT 48 h after tMCAO in the ipsilateral hemisphere 16 
(WT: 72.12 ± 4.37% vs. SIRT5-/- : 44.74 ± 7.77 %; P = 0.0106; n = 6-5; Figure 2B). 17 
BBB permeability is regulated by tight and adherens junctional proteins. During stroke the 18 
paracellular permeability increases due to the degradation of these proteins. Herein, we 19 
assessed the integrity of two transmembrane TJPs, occludin and claudin-5, using 20 
immunostainings. A reduction in occludin levels in the ipsilateral hemisphere of WT and 21 
SIRT5-/- mice compared to the contralateral hemisphere was observed (WT contralateral: 22 
0.82 ± 0.06 vs. WT ipsilateral: 0.43 ± 0.04; P = 0.0005; n=6; SIRT5-/- contralateral: 0.86 ± 23 
0.06 vs. SIRT5-/- ipsilateral: 0.61 ± 0.06; P = 0.025; n = 5; Figure 2C-D). However, occludin 24 
levels were higher in the ipsilateral hemisphere of SIRT5-/- mice compared to WT mice (WT: 25 
0.43 ± 0.04 vs. SIRT5-/- : 0.61 ± 0.064; P=0.040; n=6-5; Figure 2C-D). Similarly, claudin-5 26 
was decreased in the ipsilateral hemisphere of both groups compared to the contralateral 27 
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hemisphere (WT contralateral: 0.59 ± 0.10 vs. WT ipsilateral: 0.11 ± 0.24; P = 0.002; n=6; 1 
SIRT5-/- contralateral: 0.48 ± 0.05 vs. SIRT5-/- ipsilateral: 0.21 ± 0.06; P = 0.01; n = 5; Figure 2 
2E-F). The expression of claudin-5 did not differ between groups in the ipsilateral hemisphere 3 
(WT: 0.11 ± 0.02 vs. SIRT5-/- : 0.21 ± 0.065; P=0.18; n=5; Figure 2E-F). 4 
Deletion of SIRT5 decreases the systemic inflammatory response 5 
In ischemic stroke patients the number of circulating neutrophils increases few hours after 6 
the stroke onset while lymphocytes follow an opposite tendency.25, 26 Thus, the neutrophil-to-7 
lymphocyte ratio (NLR) is increased with stroke and correlates with stroke outcome and 8 
mortality.27 We further investigated whether SIRT5 affects the systemic inflammatory 9 
response 48 h after stroke. Total white blood cells displayed not difference between the study 10 
groups (WT: 2.41 ± 0.58 109/L vs. SIRT5-/- : 2.27 ± 0.49 109/L; P = 0.86; n = 7-5; Figure 3A). 11 
However, SIRT5-/- mice showed higher lymphocytes counts (WT: 48.75 ± 2.25% vs. SIRT5-/- : 12 
60.88 ± 2.89%; P = 0.007; n = 7-5; Figure 3B) and lower neutrophils (WT: 46.14 ± 3.27% vs. 13 
SIRT5-/- : 35 ± 2.88 %; P = 0.036; n = 7-5  Figure 3C) leading to a reduced NLR  compared 14 
to WT mice (WT: 1.21 ± 0.18 vs. SIRT5-/- : 0.68 ± 0.06; P = 0.043; n = 7-5 Figure 3D). 15 
Knockdown of SIRT5 regulates BBB permeability after H/R in HBMVECs 16 
To investigate the mechanisms underlying the blunted BBB damage and to translate our in 17 
vivo murine data to human cells, we established an in vitro BBB model consisting of a 18 
monolayer of HBMVECs seeded at confluence in ECIS electrode chambers.   Furthermore, 19 
to mimic ischemia and reperfusion occurring in the mouse, HBMVECs were subjected to 20 
hypoxia for 4 h followed by 48 h of reoxygenation and TEER values were measured during 21 
the entire experiment. SIRT5 siRNA treated cells (siSIRT5) showed higher resistance 22 
compared to scramble treated cells (siSCR) (Figure 4B). The difference between this two 23 
groups became evident 32 h after hypoxia and was augmented overtime confirming the anti-24 
permeability properties of SIRT5 knockdown (32 h: siSCR: 0.43 ± 0.04 vs. siSIRT5: 0.59 ± 25 
0.04; P = 0.01; n = 10; Figure 4B). We hypothesized that this effect was mediated by 26 
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PI3K/Akt pathway since p-Akt/Akt ratio was increased upon knockdown of SIRT5 (siSCR: 1 
1.24 ± 0.10, siSCR H/R: 1.00 ± 0.16 vs. siSIRT5 H/R: 1.47 ± 0.11; P = 0.04; n = 6; Figure 2 
4A). According to our hypothesis, the PI3K/Akt pathway inhibitor - wortmannin - blocked the 3 
effect of SIRT5 siRNA on TEER (32 h: siSIRT5: 0.59 ± 0.04 vs. siSIRT5 + WM: 0.45 ± 0.04; P 4 
= 0.04; n = 10; Figure 4B). 5 
To further elucidate the potential mechanisms accounting for the effect of SIRT5 knockdown 6 
on BBB permeability, we assessed early responses on tight and adherens junctional proteins 7 
after H/R. After 4 h of hypoxia followed by 4 h of reoxygenation, claudin-5, occludin and VE-8 
cadherin expression did not differ compared to normoxic controls (data not shown). 9 
Nevertheless, siSIRT5 treatment increased occludin and claudin-5, but not VE-cadherin (data 10 
not shown), protein expression after H/R compared to siSCR (occludin: siSCR H/R: 1 ± 0.12 11 
vs. siSIRT5  H/R: 1.33 ± 0.11; P = 0.04; n = 5; Figure 4C; claudin-5: siSCR H/R: 1 ± 0.11 vs. 12 
siSIRT5  H/R: 1.64 ± 0.24; P = 0.02; n = 7 Figure 4D). In order to investigate whether the 13 
PI3K/Akt pathway also mediates the upregulation of TJPs in the absence of SIRT5, siSIRT5 14 
HBMVECs were treated with wortmannin or vehicle (DMSO) before the hypoxic exposure. In 15 
line with the results from endothelial permeability experiments, wortmannin prevented the 16 
increase of occludin and claudin-5 after siSIRT5 (occludin: siSIRT5 H/R: 1.33 ± 0.11 vs. 17 
siSIRT5 + WM H/R: 0.87 ± 0.17; P = 0.04; n = 5; Figure 4C; claudin-5: siSIRT5 H/R: 1.64 ± 18 
0.24 vs. siSIRT5 + WM H/R: 0.64 ± 0.15; P = 0.01; n = 7 Figure 4D). Finally, we confirmed 19 
the knockdown of SIRT5 in HBMVECs. SIRT5 siRNA induced around 50% reduction in 20 
SIRT5 protein expression compared to SCR siRNA (siSCR: 1.00 ± 0.10 vs. siSIRT5: 0.47 ± 21 
0.07; P = 0.006; n = 4; Figure S2B in the Supplementary material). 22 
SIRT5 mediates the interaction of claudin-5 with Akt 23 
To confirm the involvement of the PI3K/Akt pathway in the upregulation of TJPs following 24 
SIRT5 knockdown, we performed a co-immunoprecipitation experiment. Hereby, we found 25 
that claudin-5 and occludin co-immunoprecipitate with Akt. In addition, knockdown of SIRT5 26 
enhanced the binding of claudin-5 to Akt by approximately fourfold above the scramble-27 
11 
 
treated group (Figure 5A), whereas occludin was not affected by SIRT5 silencing (Figure 1 
5B). 2 
Discussion 3 
Stroke is an age-related disease and the second-leading cause of death and disability 4 
worldwide; furthermore, its incidence is expected to rise due to the continuously increasing 5 
life expectancy. To date, the only available treatment is early recanalization which is crucial 6 
for improving prognosis in AIS patients.28 Nonetheless, reperfusion therapy can only be 7 
performed within a limited time frame from onset of symptoms and is associated with 8 
impaired BBB integrity and increased risks of intracerebral hemorrhage.6 Loss of BBB 9 
integrity correlates with worsened long-term outcome in AIS patients however, the 10 
mechanisms underlying this correlation are not clear.7 In light of the above, it is essential to 11 
identify novel molecular targets modulating BBB breakdown after reperfusion so as to 12 
develop therapeutic strategies for the treatment of AIS patients.  13 
In the present study, we demonstrate for the first time that genetic deletion or silencing of 14 
SIRT5 yields protective effects in the acute phase of ischemic stroke. Indeed, deletion of 15 
SIRT5 reduced ischemic brain damage, improved neurological outcome and decreased 16 
systemic inflammation through blunted BBB disruption and occludin degradation. In vivo 17 
findings observed in the mouse were partially reproduced in HBMVECs highlighting the 18 
translational relevance of our findings. Accordingly, HBMVECs exposed to H/R after SIRT5 19 
silencing displayed decreased endothelial permeability and increased expression of TJPs 20 
occludin and claudin-5 via activation of the PI3K/Akt pathway.  21 
Our findings demonstrate a 50% reduction in stroke size in mice lacking SIRT5 protein; 22 
further, we observed a concomitant improvement in neurological deficits at 48 h, but not 24h, 23 
after tMCAO underscoring the physiological relevance of the observed effect. Our data are in 24 
contrast to previous work describing a protective role of SIRT5 in the heart following 25 
ischemia/reperfusion,13 and thus imply a deleterious role of SIRT5 which is specific for the 26 
brain. Similarly to the data obtained in SIRT5-/- mice, in vivo knockdown of SIRT5 led to a 27 
12 
 
33% reduction in stroke size 24 h after tMCAO although, a parallel improvement in 1 
neurological deficit could not be confirmed. The latter result was rather unexpected and may 2 
be explained by a gene-dosing effect whereby knockdown only yielded a 40% decrease in 3 
SIRT5 protein as opposed to SIRT5-/- mice where SIRT5 protein was completely abrogated. 4 
Furthermore, the Bederson-based scale used to asses neurological impairment may not be 5 
the most suited approach for detecting minor changes despite being a very well established 6 
protocol.29 On the other hand, confirmation of the deleterious role of SIRT5 on stroke size 7 
using a knockdown approach adds value to the present study since in vivo knockdown by 8 
siRNA represents a clinically relevant therapeutical strategy as recently confirmed in several 9 
clinical trials.30, 31 Noteworthy, the use of knockdown animals is also relevant for excluding 10 
potential compensatory mechanisms which may take place in knockout animals where the 11 
protein of interest is lacking congenitally.32 Lastly, as previously shown by our group 12 
intravenous administration of siRNA primarily targets brain endothelial cells,18 thereby 13 
underscoring the importance of cerebral/endothelial SIRT5 in determining BBB damage and 14 
brain injury. 15 
BBB disruption is a hallmark of stroke, however, it is still controversially discussed whether it 16 
is the cause or rather the consequence of brain injury. Studies using interventions specific to 17 
the endothelium support the former view and indicate the BBB as the cause rather than the 18 
consequence of brain damage.24, 33 In line with this concept, it is of utter importance to study 19 
the spatial and temporal changes in BBB breakdown occurring after stroke and the 20 
mechanisms responsible for it. Shi et al. observed an early increase in the BBB permeability 21 
to small macromolecules (≤3 kDa) at 30 min after ischemia, whereas the increase to larger 22 
macromolecules (≥40kDa) such as IgG or serum albumin occurs 3 h after and keeps 23 
increasing progressively up to 24 h after ischemia. Extravasation of larger macromolecules 24 
across the BBB is associated with upregulation of MMPs and loss of TJPs integrity.24 In line 25 
with this data, we observed IgG extravasation and degradation of claudin-5 and occludin 26 
protein 48 h after ischemia. Importantly, SIRT5-/- mice blunted IgG extravasation and occludin 27 
13 
 
degradation indicating SIRT5 as a novel target against stroke-induced BBB leakiness and 1 
TJPs degradation.  2 
The systemic inflammatory response occurring after AIS has been proposed as a prognostic 3 
biomarker.34 Neutrophil count and neutrophil/lymphocyte ratio (NLR) are augmented in the 4 
first 3 days after onset of symptoms in stroke patients and correlate with stroke outcome.35,36 5 
In addition, experimental data showed a positive association between systemic and local 6 
inflammatory response after tMCAO.  In this regard, an increase in peripheral neutrophil 7 
count is associated with enhanced recruitment of leukocyte in cerebral microcirculation and 8 
neutrophil activation in the brain.37 This experimental and clinical evidence supports the 9 
notion that systemic inflammatory responses may parallel local inflammatory responses 10 
following stroke. Interestingly, our findings reveal a decreased systemic inflammatory 11 
response in SIRT5-/- mice as compared to WT mice which maybe the result of attenuated 12 
brain injury as observed in SIRT5-/- mice, although the cause-effect relationship remains to 13 
be established. Notwithstanding, these data concur with clinical studies in that reduced 14 
neutrophil count as well as NLR is associated with improved outcome after stroke.  15 
To assess the translational relevance of our murine findings, we established an in vitro model 16 
of HBMVECs exposed to H/R. Similarly to our in vivo data, SIRT5 silencing attenuated the 17 
increase in endothelial permeability following H/R. Moreover, this functional change was 18 
paralleled by an upregulation of claudin-5 and occludin protein suggesting this, likewise in 19 
vivo, as the responsible mechanism for the reduced permeability following SIRT5 20 
knockdown. Several studies reported that the PI3K/ Akt signaling pathway blunts stroke-21 
induced BBB disruption38-40 however, the molecular mechanisms underlying this effect are 22 
incompletely understood. In line with this observation we coincubated HBMVEC with 23 
wortmannin and found that it could abrogate the protective effects achieved by SIRT5 24 
knockdown, thereby providing direct evidence that SIRT5 signals through the PI3K/Akt 25 
pathway. In addition, we demonstrate that claudin-5 and occludin coimmunoprecipitate with 26 
Akt underscoring a direct interaction. Binding of claudin-5 to Akt was increased following 27 
14 
 
SIRT5 knockdown suggesting that the claudin-5/Akt interaction may contribute to the 1 
upregulation of claudin-5 upon SIRT5 silencing. Claudin-5 and occludin are proteins with 2 
relatively short half-life which can be degraded by the ubiquitin–proteasome system or the E3 3 
ubiquitin ligase itch, respectively.41, 42 Indeed, previous data showed that inhibition of 4 
glycogen synthase kinase 3b (GSK3β), a downstream target of Akt, upregulates claudin-5 5 
and occludin by decreasing their turnover.43 Furthermore, Camire et al. suggested that PI3K 6 
modules claudin-5 expression by regulating its degradation.44 In keeping with this concept, 7 
we postulate that as a consequence of knockdown of SIRT5, Akt may reduce TJPs turnover 8 
by direct interaction, as it is most likely the case with claudin-5, or through downstream 9 
targets such as GSK3β. Nevertheless, additional experiments are warranted in order to 10 
confirm the mechanisms underlying SIRT5 siRNA induced Akt-dependent, upregulation of 11 
TJPs. 12 
One potential limitation of the present study is that deletion or knockdown of SIRT5 was not 13 
limited to brain endothelial cells. Consequently, we cannot exclude potential effects from 14 
other organs and/or cell types. On the other hand, our in vitro data confirm the crucial 15 
contribution of brain endothelial cells, thereby supporting the proposed mechanism. Another 16 
limitation could be related to our in vitro model of H/R. TJPs were not downregulated after 4 17 
of hypoxia followed by 4 h of reoxygenation as unlike what we observed in vivo following 18 
stroke. Nevertheless, other groups did not observe reduced expression of occludin and 19 
claudin-5 after hypoxic exposure.45, 46 Independently of the above, our in vitro model showed 20 
a decrease in BBB function after exposure to H/R which was attenuated following SIRT5 21 
knockdown. 22 
In summary, this study provides first evidence for of SIRT5 in mediating brain injury and 23 
neurological deficit in a mouse model of ischemic stroke.  This effect was mediated, at least 24 
in part, by an increase in BBB permeability and tight junction proteins disruption and was 25 
reproduced also in primary HBMVECs. Findings in the present study provide a novel 26 
15 
 
molecular mechanism involved in BBB degradation following stroke and could provide a 1 
concrete platform for the development of novel therapeutic strategies.  2 
  3 
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Figures Legend 1 
Figure 1. Deletion and knockdown of SIRT5 decreases infarct volume after stroke. (A, 2 
B) Brain infarct volume at 48 h after tMCAO was measured on TTC-stained coronal sections 3 
of WT and SIRT5-/- mice (n= 9). (C) The changes in neurological scores at 2 h, 24 h, and 48 h 4 
following tMCAO in WT and SIRT5-/- mice (n=13-12). (D, E) Brain infarct volume at 24 h after 5 
tMCAO was measured on TTC-stained coronal sections of scrambled treated mice (siSCR) 6 
and SIRT5 treated mice (siSIRT5) (n=10-7). Data are expressed as mean ± SEM. *P<0.05, 7 
**P<0.01, ***P<0.001 versus WT (B, C); siSCR (E) 8 
Figure 2. Deletion of SIRT5 attenuates BBB disruption and occludin loss after stroke. 9 
(A) Representative images showing the extravasation of plasma IgG (green) into the brain 10 
parenchyma 48 h after tMCAO. (B) Volume of extravasation of endogenous IgG. (n=6-5) 11 
*P<0.05 versus WT. (C and E) Immunostaining of occludin and claudin 5 in contralateral and 12 
ipsilateral hemispheres of WT and SIRT5-/-mice. (D and F) Quantification of occludin and 13 
claudin-5 positive areas normalized to the total endothelial cell surface area (CD31 staining) 14 
in contralateral and ipsilateral hemispheres of WT and SIRT5-/- mice (n=5). Scale bar: 30 µm. 15 
Data are expressed as mean ± SEM.*P<0.05, **P<0.01, ***P<0.001 16 
Figure 3. Deletion of SIRT5 lowers the systemic inflammatory response 48 h after 17 
tMCAO. (A, B, C, D) WBC, lymphocyte, neutrophil, counts and neutrophils to lymphocytes 18 
ratio in WT and SIRT5-/- mice (n=7-5). Data are expressed as mean ± SEM. *P<0.05, 19 
**P<0.01 versus WT. WBC= white blood cells. 20 
Figure 4. Knockdown of SIRT5 decreases BBB permeability and upregulates TJPs via 21 
PI3K/Akt pathway after exposure to hypoxia and reoxygenation (H/R) in HBMVECs. (A) 22 
Western blot analysis showed increase in p-Akt/ Akt ratio after H/R in SIRT5 siRNA 23 
compared to scrambled treated cells (n=6). (B) Transendothelial Electrical Resistance 24 
(TEER) was measured continuously over 48 h in HBMVECs treated with SIRT5 siRNA and 25 
DMSO, scrambled siRNA and DMSO or SIRT5 siRNA and wortmannin (10-7 M). Resistance 26 
23 
 
measurements are normalized to its zero value (baseline period before hypoxia) and plotted 1 
as different times after hypoxia (n=10).  *P<0.05, ** P<0.01 vs. siSCR # P <0.05 vs. SIRT5+ 2 
WM (C, E)  Western blot analysis showed upregulation of occludin and claudin-5 in SIRT5 3 
treated cells after 4 h hypoxia followed by 4 h of reoxygenation. Wortmannin (10-7 M) 4 
pretreatment prevented the upregulation of TJPs induced by SIRT5 knockdown (n=5-10). 5 
Data are expressed as mean ± SEM. *P<0.05, ** P<0.01. 6 
Figure 5. Knockdown of SIRT5 enhances the binding of claudin-5 to Akt. (A) 7 
Representative immunoblot of coimmunoprecipitation of Akt and claudin-5 from whole-cell 8 
lysates of scrambled or SIRT5 siRNA treated cells after H/R. (B) Representative immunoblot 9 
of coimmunoprecipitation of Akt and occludin from whole-cell lysates of scrambled or SIRT5 10 
siRNA treated cells after H/R (n = 3) 11 
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